BridgeBio Pharma Inc vs Hormel Foods Corp — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Hormel Foods Corp trades at $24.25 (market cap $13.37B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Hormel Foods Corp pays a 4.81% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | HRL | |
|---|---|---|
Market Cap | $16.36B | $13.37B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $29.25 |
52-Week Low | $47.29 | $19.74 |
Enterprise Value | $18.14B | $15.37B |
Dividend Yield | — | 4.81% |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →